Cingulate continues stock-for-debt exchanges to reduce liabilities

The score is held back mainly by weak financial performance (pre-revenue, widening losses, and persistent cash burn). Offsetting this are meaningful positive corporate milestones (FDA NDA acceptance ...
Yahoo Finance

Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Benzinga.com

What's Going On With Cingulate Shares Recently?

Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...
Benzinga.com

Cingulate Shares Are Trading By More Than 200% Friday: What You Need To Know

Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...
The Business Journals

KC-area pharmaceutical company starts its last trial before seeking FDA approval

The pharmaceutical company is entering the final stretch of clinical trials and studies before submitting for FDA approval, the culmination of a long haul for its medication. A Kansas City, Kansas, ...
The Business Journals

As Cingulate labors to push its first drug through trials, it sees executives, board members depart

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Cingulate's recent SEC filings ...
FiercePharma

Cingulate posts clinical data on once-daily, triple-release anxiety tablet

Cingulate has posted pharmacokinetic data from an early-phase clinical trial of its triple-release anxiety drug candidate, providing itself with a platform to support development of a planned ...
Yahoo Finance

Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance

KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- In alignment with U.S. Food and Drug Administration (FDA) requirements, Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its ...
Nasdaq

Cingulate Inc. Provides Clinical Update on CTx-1301 Pre-NDA Meeting and Announces $3 Million Grant for CTx-2103 Development

Cingulate Inc. completes FDA Pre-NDA meeting for ADHD drug CTx-1301 and secures $3 million grant for anxiety treatment CTx-2103. Cingulate Inc. announced the successful completion of a Pre-NDA meeting ...